View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …

View Post

Veru touts novel breast cancer treatment strategy as drug nears phase 3

In Clinical Studies News by Barbara Jacoby

By: Angus Liu From: fiercebiotech.com Hormone therapies, or endocrine therapies, are widely used to treat breast cancer that is estrogen receptor (ER)-positive, but resistance is a common problem. That has sparked interest in drugs targeting the androgen receptor (AR). But the role of AR in ER-positive disease remains unclear, leading to the development of both AR agonists and antagonists. Now …

View Post

Estradiol Challenge Test ‘Highly Predictive’ of Response to Endocrine Therapy in Patients With ER-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Leah Lawrence From: cancertherapyadvisor.com The use of a positron emission tomography (PET)-based estradiol challenge test was found to be highly predictive of response to endocrine therapy in women with estrogen-receptor (ER)-positive breast cancer. In the phase 2 study (NCT02455453), data from which were published in Nature Communications, the investigators measured the responses to endocrine therapy by monitoring the change …

View Post

Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Brooklyn ImmunoTherapeutics From: businesswire.com Brooklyn ImmunoTherapeutics LLC (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda®) and chemotherapy in triple negative breast cancer (TNBC). The trial will be conducted at the …

View Post

Endoxifen Shows Promise in Treating Breast Cancer in Australian Trial, Development in the US to Accelerate

In Clinical Studies News by Barbara Jacoby

By: Ryan McDonald From: curetoday.com Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S. Treatment with oral endoxifen during the “window of opportunity” between breast cancer diagnosis and …

View Post

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com Investigators are seeking to determine whether amcenestrant (SAR439859), an investigational oral endocrine therapy, can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer. The phase 2 AMEERA-4 trial (NCT04191382) is testing 2 dose levels of amcenestrant versus letrozole given for 14 days to patients with …

View Post

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Ayala Pharmaceuticals From: globenewswire.com Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic …

View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase 2 Trial

In Clinical Studies News by Barbara Jacoby

Source: Translational Research in Oncology From: globenewswire.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of the first patient in a Phase 2 randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche. GDC-9545 is a selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity …